정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2074 | Active, not recruiting | CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms | SARS-CoV2 | Drug: Cannabidiol Other: PLACEBO |
Phase 3 | University of Sao Paulo, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo | OTHER | 100 | All | 18 Years | Servico de Assistencia Medica e Social do Pessoal do Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil Unidade de Pronto Atendimento/UPA - 13 de Maio/Dr. Luis Atilio Losi Viana (UPA Covid), Ribeirao Preto, Sao Paulo, Brazil |
2073 | Recruiting | Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors | Cardiovascular Risk Factor | Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC Drug: Placebo |
Phase 3 | Cardiol Therapeutics Inc. | INDUSTRY | 422 | All | 18 Years | Valleywise Health Medical Center, Phoenix, Arizona, United States Westchester General Hospital, Miami, Florida, United States Med-Care Research, Miami, Florida, United States University of South Florida, Tampa, Florida, United States Prairie Education and Research Cooperative, Springfield, Illinois, United States Lutheran Health Physicians, Fort Wayne, Indiana, United States Montefiore Medical Center (MMC), Bronx, New York, United States PRX Research/Dallas Regional Medical Center, Mesquite, Texas, United States University of Texas Health Science Center, San Antonio, Texas, United States Baylor Scott & White Health - Temple, Temple, Texas, United States |
2072 | Recruiting | Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection | COVID-19 | Drug: Cannabidiol | Phase 2 | Rabin Medical Center | OTHER | 40 | All | 18 Years | Rabin Medical Center, Petach Tikva, Israel |
2071 | Completed | Cardiovascular Effects of COVID-19 | COVID-19 | Drug: AT-001 | Phase 2 | NYU Langone Health | OTHER | 81 | All | 18 Years | NYU Langone Health, New York, New York, United States |
2070 | Recruiting | Catalysing the Containment of COVID-19 | COVID-19 | Drug: Nitazoxanide Drug: Placebo |
Phase 3 | University of Cape Town, Medical Research Council, South Africa, Aurum Institute, National Institutes of Health (NIH), Texas Tech University Health Sciences Center, University of KwaZulu, Perinatal HIV Research Unit of the University of the Witswatersrand | OTHER | 440 | All | 18 Years ~ 120 Years | The Aurum Institute, Tembisa, Gauteng, South Africa University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa Perinatal HIV Research Unit, Klerksdorp, North West, South Africa University of Cape Town, Cape Town, Western Cape, South Africa |
2069 | Not yet recruiting | CBT-I or Zolpidem/Trazodone for Insomnia | Chronic Insomnia | Drug: Zolpidem Behavioral: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) Drug: Trazodone |
Phase 4 | California Pacific Medical Center Research Institute, Patient-Centered Outcomes Research Institute, University of Pittsburgh, University of Arizona, University of Virginia, University of Illinois at Chicago | OTHER | 1200 | All | 18 Years ~ 80 Years | University of Alabama at Birmingham, Birmingham, Alabama, United States University of Arizona, Tucson, Arizona, United States University of California, San Francisco-Fresno, Fresno, California, United States National Jewish Health, Denver, Colorado, United States University of Missouri, Columbia, Missouri, United States Oregon Health & Science University, Portland, Oregon, United States Penn State Hershey Medical Center, Hershey, Pennsylvania, United States University of Pittsburgh, Pittsburgh, Pennsylvania, United States University of Virginia, Charlottesville, Virginia, United States |
2068 | Completed | CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) | Coronavirus Disease 2019 (COVID-19) | Drug: CD24Fc Drug: Placebo |
Phase 3 | OncoImmune, Inc. | INDUSTRY | 234 | All | 18 Years | Baptist Health Research Institute, Jacksonville, Florida, United States Anne Anundel Medical Center, Annapolis, Maryland, United States Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States Shady Grove Medical Center, Rockville, Maryland, United States White Oak Medical Center, Silver Spring, Maryland, United States Cooper University Hospital, Camden, New Jersey, United States Atlantic Health System, Morristown, New Jersey, United States University Hospitals of Cleveland, Cleveland, Ohio, United States The Ohio State University Medical Center, Columbus, Ohio, United States University of Texas at Houston, Houston, Texas, United States |